← 返回

IL-15 作为 NK 细胞介导肿瘤免疫治疗的关键调控因子:从基础到临床

英文原题:IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside.

查看英文原题

IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside.

PubMed 2024/04/25(内容时间) Int Immunopharmacol Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

白细胞介素-15(IL-15)已成为自然杀伤(NK)细胞与癌症免疫疗法关系中的关键因素。本综述旨在全面阐述 IL-15 在 NK 细胞介导免疫治疗中的作用。首先讨论 IL-15 信号在 NK 细胞免疫中的关键作用,重点介绍其对 NK 细胞功能和抗肿瘤特性的调节。

此外,综述探讨将 IL-15 或其类似物用于多种癌症临床试验的治疗策略,包括通过基因修饰使 NK 细胞产生 IL-15。研究还考察了基于 IL-15 的疗法的潜力,例如 CAR-T 或 NK 细胞输注联合 IL-15,以及 IL-15 与检查点抑制剂和其他治疗联合。本综述还讨论在细胞免疫治疗中纳入 IL-15 的挑战和优势。

此外,文章探讨了一些尚未解决的问题,包括可溶性 IL-15/IL-15R 复合物的检测及其生物学意义、IL-15/IL-15R 在人类癌症中的潜在作用,以及 NK 细胞长期暴露于可溶性 IL-15 的免疫学后果。

展开英文摘要原文

Interleukin 15 (IL-15) has emerged as a crucial factor in the relationship between natural killer (NK) cells and immunotherapy for cancer. This review article aims to provide a comprehensive understanding of the role of IL-15 in NK cell-mediated immunotherapy. First, the key role of IL-15 signaling in NK cell immunity is discussed, highlighting its regulation of NK cell functions and antitumor properties.

Furthermore, the use of IL-15 or its analogs in clinical trials as a therapeutic strategy for various cancers, including the genetic modification of NK cells to produce IL-15, has been explored. The potential of IL-15-based therapies, such as chimeric antigen receptor (CAR) T and NK cell infusion along with IL-15 in combination with checkpoint inhibitors and other treatments, has been examined. This review also addresses the challenges and advantages of incorporating IL-15 in cell-based immunotherapy.

Additionally, unresolved questions regarding the detection and biological significance of the soluble IL-15/IL-15R complex, as well as the potential role of IL-15/IL-15R in human cancer and the immunological consequences of prolonged exposure to soluble IL-15 for NK cells, are discussed.

论文信息

作者
Vahidi S、Zabeti Touchaei A、Samadani AA
第一作者单位
Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: so.vahidii@gmail.com.Iran
通讯作者单位
Guilan Road Trauma Research Center, Trauma Institute, Guilan University of Medical Sciences, Rasht, Iran. Electronic address: a.a.hormoz@gmail.com.Iran
文献类型
综述
期刊
International immunopharmacology2024 May 30
原文标识
PubMed 38669950 · DOI 10.1016/j.intimp.2024.112156